Jove
Visualize
联系我们

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026
Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Molly Olzinski1, Yann Cobigo2, Rowan Saloner1

  • 1Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

下脑脊液 (CSF) TMEM106B水平与前叶退化 (FTLD) 严重程度增加和大脑缩相关. CSF TMEM106B可以作为FTLD中神经退行的一个有价值的生物标志物.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 遗传学 遗传学 是一个
  • 生物标志物发现发现

背景情况:

  • TMEM106B是一种 lysosomal 蛋白质,是前叶退化症 (FTLD) 的遗传风险因素.
  • 基于aptamer的蛋白质组学可以量化CSFTMEM106B.
  • 作为FTLD严重程度的生物标志物,CSF TMEM106B的临床实用性尚未评估.

研究的目的:

  • 调查CSFTMEM106B水平与FTLD疾病严重程度之间的关联.
  • 探索CSF TMEM106B,神经退行和大脑缩之间的关系.
  • 确定CSFTMEM106B作为FTLD临床生物标志物的潜力.

主要方法:

  • 在两个独立的FTLD队列 (偶发性和家族性) 中,CSF TMEM106B和NfL蛋白质水平使用基于aptamer的蛋白质组测量.
  • 统计分析,包括线性和混合线性模型,评估生物标志物和疾病严重程度指标之间的关联 (例如CDR®+NACC-FTLD).
  • 基于voxel的形态学分析了CSF生物标志物与大脑体积之间的相关性.

主要成果:

  • 较低的CSFTMEM106B水平与更大的FTLD疾病严重程度,功能衰退,认知障碍和抑郁症有关.
  • 低的CSFTMEM106B与前额,顶部和部区域的大脑体积减少相关.
  • CSF NfL与疾病严重程度的关联较强,而CSF TMEM106B与大脑体积的关联较强.

结论:

  • 脑流TMEM106B度受rs1990622基因型的影响,与FTLD疾病严重程度和大脑缩相关.
  • 较低的CSFTMEM106B水平表明FTLD中更严重的神经退行和大脑体积损失.
  • CSF TMEM106B显示出作为FTLD神经退行症生物标志物的潜力,补充了CSF NfL.